Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05285696 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate the Safety and Dosimetry of [68Ga]-NOTA-hGZP (CSB-111) PET Imaging in Healthy Human Volunteers.

A Phase 1 study of Healthy Volunteers, sponsored by Cytosite Biopharma.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT05285696 is a Phase 1 study of Healthy Volunteers that has completed, run by Cytosite Biopharma. The registered enrollment target is 6 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05285696, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Cytosite Biopharma.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

Phase one study to evaluate the safety and dosimetry of \[68Ga\]-NOTA-hGZP (CSB-111) PET Imaging in healthy human volunteers.

Conditions Studied

Interventions

  • DRUG CSB-111

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2022-09-01
Est. Completion 2023-05-20
Phase Phase 1

Sponsor

Cytosite Biopharma

3 total trials

What the Registry Record Tells You About NCT05285696

The ClinicalTrials.gov registry entry for NCT05285696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (99% lower). The listed sponsor is Cytosite Biopharma, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which CSB-111 is the first listed.

NCT05285696 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT05285696 about?

NCT05285696 is a clinical study titled "Study to Evaluate the Safety and Dosimetry of [68Ga]-NOTA-hGZP (CSB-111) PET Imaging in Healthy Human Volunteers.". Phase one study to evaluate the safety and dosimetry of \[68Ga\]-NOTA-hGZP (CSB-111) PET Imaging in healthy human volunteers.

What is the current status of trial NCT05285696?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-09-01. Estimated completion is 2023-05-20.

What conditions does trial NCT05285696 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT05285696?

The interventions under investigation include: CSB-111 (DRUG).

Who is sponsoring clinical trial NCT05285696?

This trial is sponsored by Cytosite Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05285696 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.